Eli Lilly tops revenue estimates on boost from diabetes drugs

Eli Lilly and Co beat analysts' estimates for quarterly profit on Tuesday and raised its full-year earnings forecast, as higher sales of diabetes drugs Trulicity and Basaglar offset competition for its erectile dysfunction drug, Cialis.